

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1                    1.-37. (Canceled).

1                    38.     (Currently Amended) A method as in claim 54, wherein ~~for inhibiting~~  
2 ~~restenosis in a blood vessel following recanalization of the blood vessel, said method~~  
3 ~~comprising:~~  
4                    ~~implanting a vascular prosthesis in the blood vessel; and~~  
5                    ~~releasing~~ methylprednisolone is released from the prosthesis at a rate between 5  
6  $\mu\text{g/day}$  to 200  $\mu\text{g/day}$ .

1                    39.     (Previously Presented) A method as in claim 38, wherein  
2 methylprednisolone is released at a rate between 10  $\mu\text{g/day}$  to 60  $\mu\text{g/day}$ .

1                    40.     (Currently Amended) A method as in claim 54 38, wherein  
2 methylprednisolone is released from the prosthesis within a time period of 1 day to 45 days in a  
3 vascular environment.

1                    41.     (Previously presented) A method as in claim 40, wherein  
2 methylprednisolone is released within a time period of 7 days to 21 days in a vascular  
3 environment.

1                    42.     (Currently Amended) A method as in claim 55 38, further comprising  
2 releasing the at least one other substance simultaneously with methylprednisolone from the  
3 prosthesis.

1                    43.    (Currently Amended) A method as in claim 55 38, further comprising  
2 releasing the at least one other substance sequentially with methylprednisolone from the  
3 prosthesis.

1                    44.    (Canceled).

1                    45.    (Currently Amended) A method as in claim 54 38, wherein the releasing  
2 comprises delaying substantial release of methylprednisolone for at least one hour following  
3 implantation of the prosthesis.

1                    46.    (Previously Presented) A method as in claim 45, wherein delaying  
2 release comprises slowing releasing methylprednisolone from a reservoir with a material that at  
3 least partially degrades in a vascular environment over said one hour.

1                    47.    (Previously Presented) A method as in claim 45, wherein delaying  
2 release comprises slowing releasing methylprednisolone with a matrix that at least partially  
3 degrades in a vascular environment over said one hour.

1                    48.    (Previously Presented) A method as in claim 45, wherein delaying  
2 release comprises slowing releasing methylprednisolone with a nondegradable matrix that  
3 allows diffusion of methylprednisolone through the nondegradable matrix after said one hour.

1                    49.    (Previously Presented) A method as in claim 45, wherein delaying  
2 release comprises slowing releasing methylprednisolone with a rate limiting barrier that allows  
3 diffusion of methylprednisolone through the barrier after said one hour.

1                    50.    (Original) A method as in any one of claims 47-49, wherein the  
2 prosthesis is coated with the matrix or barrier by spraying, dipping, deposition, or painting.

1                    51.-53. (Canceled).

1                    54.     (Previously Presented) A method for inhibiting restenosis in a blood  
2 vessel following recanalization of the blood vessel, said method comprising:  
3                    implanting a vascular prosthesis in the blood vessel; and  
4                    releasing methylprednisolone and mycophenolic acid from the prosthesis when  
5 implanted in the blood vessel.

1                    55.     (Previously Presented) A method for inhibiting restenosis in a blood  
2 vessel following recanalization of the blood vessel, said method comprising:  
3                    implanting a vascular prosthesis in the blood vessel; and  
4                    releasing methylprednisolone and at least one other substance in addition to  
5 methylprednisolone from the prosthesis when implanted in the blood vessel, wherein the at least  
6 one other substance comprises mizoribine.

1                    56.     (Currently Amended) A method as in claim 54 ~~38~~, ~~further comprising~~  
2 ~~releasing at least one other substance in addition to methylprednisolone from the prosthesis~~  
3 ~~when implanted in the blood vessel~~, wherein methylprednisolone is substantially released  
4 within a time period of 2 days to 3 months.

1                    57.     (Canceled).

1                    58.     (Currently Amended) A method as in claim 54 ~~56~~, wherein  
2 methylprednisolone and mycophenolic acid ~~the at least one additional substance~~ are released  
3 simultaneously.

1                    59.     (Currently Amended) A method as in claim 54 ~~56~~, wherein  
2 methylprednisolone and mycophenolic acid ~~the at least one additional substance~~ are released  
3 sequentially.

1                    60.-61. (Canceled)

1                   62.     (New) A method as in claim 55, wherein methylprednisolone is released  
2 from the prosthesis at a rate between 5  $\mu\text{g/day}$  to 200  $\mu\text{g/day}$ .

1                   63.     (New) A method as in claim 62, wherein methylprednisolone is released  
2 at a rate between 10  $\mu\text{g/day}$  to 60  $\mu\text{g/day}$ .

1                   64.     (New) A method as in claim 55, wherein methylprednisolone is released  
2 from the prosthesis within a time period of 1 day to 45 days in a vascular environment.

1                   65.     (New) A method as in claim 64, wherein methylprednisolone is released  
2 within a time period of 7 days to 21 days in a vascular environment.

1                   66.     (New) A method as in claim 55, wherein the releasing comprises  
2 delaying substantial release of methylprednisolone for at least one hour following implantation  
3 of the prosthesis.

1                   67.     (New) A method as in claim 66, wherein delaying release comprises  
2 slowing releasing methylprednisolone from a reservoir with a material that at least partially  
3 degrades in a vascular environment over said one hour.

1                   68.     (New) A method as in claim 66, wherein delaying release comprises  
2 slowing releasing methylprednisolone with a matrix that at least partially degrades in a vascular  
3 environment over said one hour.

1                   69.     (New) A method as in claim 66, wherein delaying release comprises  
2 slowing releasing methylprednisolone with a nondegradable matrix that allows diffusion of  
3 methylprednisolone through the nondegradable matrix after said one hour.

1                   70.     (New) A method as in claim 66, wherein delaying release comprises  
2 slowing releasing methylprednisolone with a rate limiting barrier that allows diffusion of  
3 methylprednisolone through the barrier after said one hour.

1                   71.     (New) A method as in any one of claims 68-70, wherein the prosthesis is  
2     coated with the matrix or barrier by spraying, dipping, deposition, or painting.

1                   72.     (New) A method as in claim 55, wherein methylprednisolone is  
2     substantially released within a time period of 2 days to 3 months.